BIO-B
Bio-Rad Laboratories, Inc.
NYSE · Healthcare · Medical - Devices · US
$381.37
+4.46%Year over year
Reported trailing growth
- Revenue
- +1.4%
- EBITDA
- -22.1%
- EBIT
- +5.1%
- EPS
- -29.2%
- Free cash flow
- +1.6%
- Operating cash flow
- -7.8%
Forward estimates
Based on analyst estimates
- Revenue
- +1.3%
- EBITDA
- +9.2%
- EPS
- +29.3%
Three-year CAGR
- Revenue
- -2.7%
- EBITDA
- +158.4%
- EBIT
- -17.6%
- Net income
- +141.2%
- EPS
- +142.6%
- Free cash flow
- +67.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026